Within subject cross‐tissue analyzes of epigenetic clocks in substance use disorder postmortem brain and blood
Cabrera‐Mendoza B, Stertz L, Najera K, Selvaraj S, Teixeira A, Meyer T, Fries G, Walss‐Bass C. Within subject cross‐tissue analyzes of epigenetic clocks in substance use disorder postmortem brain and blood. American Journal Of Medical Genetics Part B Neuropsychiatric Genetics 2022, 192: 13-27. PMID: 36056652, PMCID: PMC9742183, DOI: 10.1002/ajmg.b.32920.Peer-Reviewed Original ResearchConceptsSubstance use disordersStimulant use disorderUse disordersPostmortem brainsAlcohol use disorderBrains of individualsBlood tissueBiological agingSubgroup analysisBrain valuesEpigenetic clocksSUD groupPeripheral measuresAging StudyDisordersBrainPatientsBloodDNA methylation changesSame individualTissueIndividualsMethylation changesOpioidsTissue specificityCandidate pharmacological treatments for substance use disorder and suicide identified by gene co‐expression network‐based drug repositioning
Cabrera‐Mendoza B, Martínez‐Magaña J, Monroy‐Jaramillo N, Genis‐Mendoza A, Fresno C, Fries GR, Walss‐Bass C, Armenta M, García‐Dolores F, Díaz‐Otañez C, Flores G, Vázquez‐Roque R, Nicolini H. Candidate pharmacological treatments for substance use disorder and suicide identified by gene co‐expression network‐based drug repositioning. American Journal Of Medical Genetics Part B Neuropsychiatric Genetics 2021, 186: 193-206. PMID: 33403748, DOI: 10.1002/ajmg.b.32830.Peer-Reviewed Original ResearchConceptsSubstance use disordersUse disordersBrain gene co-expression networksHub genesPotential pharmacological targetPost-mortem samplesPharmacological treatmentHigh riskCandidate treatmentPharmacological targetsSuicidal behaviorMAOA inhibitorsPrefrontal cortexNonsuicidesDGIdb databaseGene expression profilesPatientsCo-expression networkSuicideDisordersDrugsTreatmentDrug repositioningExpression profilesIndividuals